The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...
Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...
US FDA approves Novartis’ Itvisma, the only gene replacement therapy for children two years and older, teens, and adults with SMA: Basel Wednesday, November 26, 2025, 09:00 Hrs ...
ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...
Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.
A newly identified disorder, MINA syndrome, results from a mutation in the NAMPT protein that deprives motor neurons of energy, leading to severe movement problems. The discovery not only deepens ...
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III ...
An experiment with mice reveals that microscopic facial signals can betray mental strategies, reopening the debate on neural ...
Want to know who's the best at doing do-gooding work? Take a look at the finalists for the Best Pro Bono Campaign.
One of the most important functions of interneurons in the knee-jerk reflex is to mediate reciprocal inhibition. This process ensures that the contraction of the quadriceps muscle is accompanied by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback